Comparative Untargeted Metabolomic Profiling of Induced Mitochondrial Fusion in Pancreatic Cancer.
Nicholas D NguyenMeifang YuVinit Y ReddyAriana C Acevedo-DiazEnzo C MesarickJoseph Abi JaoudeMin YuanJohn M AsaraCullen M TaniguchiPublished in: Metabolites (2021)
Mitochondria are dynamic organelles that constantly alter their shape through the recruitment of specialized proteins, like mitofusin-2 (Mfn2) and dynamin-related protein 1 (Drp1). Mfn2 induces the fusion of nearby mitochondria, while Drp1 mediates mitochondrial fission. We previously found that the genetic or pharmacological activation of mitochondrial fusion was tumor suppressive against pancreatic ductal adenocarcinoma (PDAC) in several model systems. The mechanisms of how these different inducers of mitochondrial fusion reduce pancreatic cancer growth are still unknown. Here, we characterized and compared the metabolic reprogramming of these three independent methods of inducing mitochondrial fusion in KPC cells: overexpression of Mfn2, genetic editing of Drp1, or treatment with leflunomide. We identified significantly altered metabolites via robust, orthogonal statistical analyses and found that mitochondrial fusion consistently produces alterations in the metabolism of amino acids. Our unbiased methodology revealed that metabolic perturbations were similar across all these methods of inducing mitochondrial fusion, proposing a common pathway for metabolic targeting with other drugs.
Keyphrases
- oxidative stress
- mass spectrometry
- genome wide
- cell death
- gene expression
- palliative care
- single cell
- diabetic rats
- cell proliferation
- ms ms
- dna methylation
- signaling pathway
- amino acid
- copy number
- klebsiella pneumoniae
- combination therapy
- endothelial cells
- replacement therapy
- gas chromatography mass spectrometry
- high resolution
- endoplasmic reticulum